ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Core Insights - The combination of ALX Oncology's evorpacept with rituximab and lenalidomide (R2) shows promising anti-tumor activity and was well-tolerated in patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) [1][2][4] - The trial reported a complete response (CR) rate of 83% in patients with indolent NHL, significantly higher than the historical CR rate of 34% for R2 alone [1][3] - The ongoing Phase 2 trial in previously untreated indolent NHL has completed enrollment, indicating continued evaluation of evorpacept's efficacy [1][4] Company Overview - ALX Oncology is a clinical-stage biotechnology company focused on developing novel therapies for cancer treatment, with evorpacept as its lead candidate [7] - The company aims to address unmet needs in cancer treatment by enhancing the effectiveness of existing therapies [4][7] Clinical Trial Details - The Phase 1/2 trial included 20 patients, with 18 having indolent and 2 having aggressive R/R B-NHL, all of whom had previously received anti-CD20 monoclonal antibodies [2] - The trial demonstrated a two-year progression-free survival (PFS) rate of 69% and an overall survival (OS) rate of 84% after a median follow-up of 28 months [3] - The trial's results will be presented at the AACR 2025 Annual Meeting, highlighting the significance of evorpacept in cancer therapy [5][6]